Evidence[edit | edit source]
Evidence for the use of nimodipine in patients with ME/CFS is extremely limited, mostly based on personal experiences rather than clinical trials, and with mixed results reported in patients.
In 1996, Dr Ellen Wiebe published case studies of two patients with ME/CFS, including a moderately ill patient who noticed improvements in fatigue, cognitive function and muscle pain after starting nimodipine. In 1998, three British doctors with a special interest in ME/CFS, stated that in their experience nimodipine and other calcium channel blockers were ineffective in patients chronic fatigue syndrome.
Notable studies[edit | edit source]
Articles and blogs[edit | edit source]
- 2016, NIMODIPINE use in ME/CFS: An introduction - Susan Parker
- 2014 Nimopidine use in ME/CFS: A comprehensive guide- Susan Parker
- Jan 28, 2008, Brief notes on Nimodipine and ME/CFS - M.E. Association
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- "Nimotop (Nimodipine): Uses, Dosage, Side Effects, Interactions, Warning". RxList. Retrieved August 29, 2020.
- "Nimodipine". www.drugbank.ca. Retrieved August 28, 2020.
- "Nimodipine". Drugs.com. Retrieved August 28, 2020.
- Wiebe, E. (November 1996). "N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports". Canadian Family Physician. 42: 2214–2217. ISSN 0008-350X. PMC 2146911. PMID 8939323.
- Chaudhuri, A; Behan, WMH; Behan, PO (1998). "Chronic fatigue syndrome" (PDF). Proc R Coll Physic Edinb. 28: 150–163.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.
T2 hyperintensity An unusual bright spot on a T2-weighted MRI of the brain. Also known as an Unidentified Bright Object (UBO). T2 hyperintensities are often found in the periventricular region, where they may be referred to as "white matter hyperintensities" or "leukoaraiosis". They may also be found in the basal ganglia or brainstem, where they are sometimes referred to as "gray matter hyperintensities", or "subcortical hyperintensities". T2 hyperintensities can represent different things: lesions, dilated Virchow-Robin spaces, or demyelination. They are commonly found in elderly individuals and in neurological disorders. (Learn more: www.ncbi.nlm.nih.gov)